Three in vitro methods for the prediction of the skin sensitization hazard have been validated. However, predicting sensitizer potency is a key requirement for risk assessment. Here, we report a database of 312 chemicals tested in the KeratinoSens TM assay and for kinetic peptide binding. These data were used in multiple regression analysis against potency in the local lymph node assay (LLNA). The dataset covers the majority of chemicals from the validation of the LLNA to predict human potency and this subset was analyzed for prediction of human sensitization potency by in vitro data. Global analysis yields a regression of in vitro data to LLNA pEC3 with an R 2 of 60% predicting LLNA EC3 with a mean error of 3.5-fold. The highest weight in the regression has the reaction rate with peptides, followed by Nrf2-induction and cytotoxicity in KeratinoSens
containing both lysine and cysteine residues is used and analysis is performed by liquid chromatography coupled to mass spectrometry (LC-MS) to determine adduct formation in addition to recording peptide depletion (Natsch and Gfeller, 2008) . This latter approach also contains a profiling at an early time point for highly reactive chemicals. A number of other test systems were proposed, measuring gene expression of a wider set of pathways (Johansson et al., 2011) , other target genes (Lambrechts et al., 2010; van der Veen et al., 2012) or sensitizerspecific inflammation markers (Gibbs et al., 2013) .
The validation studies focused on binary classification to predict hazard, yet in order to fully replace animal testing, the alternative approaches should be able to inform risk assessment and give an estimate of sensitizer potency. Ideally, information from several alternative approaches would be combined to predict a dose-per area (routinely expressed as mg/cm 2 ) threshold for sensitization induction, which can be applied as point of departure in quantitative risk assessment (QRA). ECVAM has issued a recommendation on the KeratinoSens TM assay suggesting further work to assess how dose-response information contributes to potency assessment and QRA. The use of human reference data was highlighted, and combining Nrf2-induction with other information sources, in particular peptide reactivity assays, were emphasized (ECVAM, 2014b) . Most in vitro and in chemico assays yield quantitative data and comparing these with quantitative human and animal data is possible. Data from multiple endpoints may feed into a potency assessment: we performed an early analysis integrating DPRA and Nrf2-induction data , combining Nrf2 response and glutathione binding (McKim et al., 2010) or cytotoxicity and specific gene expression (Lambrechts et al., 2010) were also proposed. Recently, a dataset on 145 chemicals from the endpoints in the validation studies were analyzed with a Bayesian net , with promising results to predict 4 sensitizer potency classes, but not yet to predict a dose-per area or EC3 values (Estimated concentration of a substance producing a stimulation index of 3 in the local lymph node assay [LLNA] ). Good correlation to LLNA EC3 values for individual parameters from single assays was shown for very specific sets of chemicals (Delaine et al., 2011; Natsch et al., 2011b; Roberts and Natsch, 2009) .
The best target for potency prediction remains an open question. Prediction of potency bands has advantages in grouping information and allowing for categorization of ingredient potency, but does not equally treat those ingredients that may be at the high or low end of the potency band, for example, if the band is used as a basis to set a No Expected Sensitization Induction Level (NESIL). Prediction of a probable EC3 value may present advantages in that it would allow for a continuous scale of potency prediction and the management of uncertainty using statistical tools based on knowledge on the accuracy of the prediction. Such uncertainty may then be taken into account when setting the NESIL to be used in risk assessment.
There is an active debate on how to best arrive at potency predictions. One proposal is to build models within mechanistic applicability domains (chemicals reacting by particular reaction mechanisms) (Aptula et al., 2005) . This approach uses the chemical structure as key input, and in vitro and in chemico data may be used for quantitative predictions within domains defined based on structural alerts or experimental information on reaction mechanism. The second approach is to build a "global" model not taking into account chemical domains. There is strong empirical support for domain-based models, but they have downsides: (1) not all chemicals belong to domains with sufficient in vivo evidence, and (2) attribution to domains involves at least some expert judgment. The two approaches may also be combined-a concept we had proposed but not yet explored based on data. Figure 1 shows such a paradigm.
Here, we report and analyze an extended dataset to evaluate (1) contribution of the in vitro parameters for LLNA potency assessment, (2) comparison of prediction of human and LLNA potency by the in vitro parameters, and (3) comparing a global model for all chemicals to domain-based models. This study also responds to the further actions proposed in the ECVAM recommendation (ECVAM, 2014b) .
MATERIALS AND METHODS

Database of Chemicals Tested In Vitro and in the LLNA
The main database used in this analysis consists of two data sources:
(1) 144 of the 145 chemicals used in a recent integrated testing strategy ) (2) The set of chemicals used in the ECVAM validation of KeratinoSens TM assay. This latter dataset consists of: (i) a set of 114 chemicals selected mainly from the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) validation of the LLNA (Haneke et al., 2001) and the ICCVAM database (ICCVAM, 2008) with congruent data in LLNA and guinea pig and/or humans; see attachment 12b in (ECVAM, 2014c) for this list; (ii) studies on specific groups of chemicals in SAR analysis (Ball et al., 2011; Delaine et al., 2011) ; (iii) a set of additional chemicals for which only negative sensitization evidence from the LLNA was available, which was used to balance the number of positives and negative chemicals in the validation data set, as the number of available non-sensitizers with congruent human/guinea pig and LLNA data was too small.
These two sets are partly overlapping, but (2) contains 100 chemicals in addition to the 144 chemicals from the dataset of 145 . This published set (n ¼ 244) of chemicals is considered the most robust database and was used for a global assessment of potency predictions in the LLNA.
(3) We present a further unpublished set of chemicals (n ¼ 68) tested in KeratinoSens TM and peptide reactivity, for which only LLNA data are available or for which LLNA and human (Natsch, 2014) data are contradictory. Evidence for sensitizer status in some of these chemicals is less clear. We present and use these data as a further test set and to enrich the datasets for individual chemical domains, but given the lower in vivo evidence did not use them to build the global model.
For prediction of LLNA potency we excluded metals for two reasons: (i) They are not in the applicability domain of peptide reactivity assays, and (ii) there is no actual need for a predictive model to predict potency of metals, as no new metal ions need toxicological assessment.
Database of Chemicals Tested In Vitro and in Humans
Different sources of human potency data are available. Although some compilations combined no observed effect level data (NOEL) with lowest observed effect level data (LOEL), the validation of the LLNA by ICCVAM followed the stringent principle of only using LOEL data, that is, only studies with positive sensitization evidence. We chose to use this publicly available data set (ICCVAM, 2011) (n ¼ 76), and tested all chemicals in this set which were clearly identified (n ¼ 71). The database reports DSA 05 values (Induction dose per skin area, in lg/cm 2 , in a human repeatinsult patch test (HRIPT) or human maximization test (HMT) that produces a positive response in 5% of the tested population). Metals were included in some analysis as indicated, to keep the dataset as close as possible to the ICCVAM validation dataset.
Standard testing of chemicals in the KeratinoSens
TM cell line. The standard operating procedure described before (Natsch et al., 2011a) and published online (ECVAM, 2014d) was used to test additional chemicals in the KeratinoSens TM assay. For each chemical the EC1.5 KS -, EC2 KS -and EC3 KS values (concentration in mM for 1.5-, 2-, and 3-fold induction of the luciferase activity) were calculated along with IC50 KS values for the concentration yielding 50% reduction in cellular viability.
Peptide reactivity assessment. The LC-MS-based assay reported before (Natsch and Gfeller, 2008) was applied to all chemicals. In this approach, depletion of the test peptide Cor1-C420 (0.1 mM start concentration) after 24 h by test chemical (1 mM) is determined. Due to presence of both cysteine and lysine in the peptide, both cysteine and lysine-reactive chemicals react with and deplete this peptide. At the same time adduct formation between peptides and test chemicals and chemical-induced peptide oxidation are measured by LC-MS. For strongly reactive chemicals which yield >50% peptide depletion at 24 h, the rate constant derived at 24 h can be an underestimation (Roberts and Natsch, 2009 ) and we used a tiered approach to determine maximal reaction rate for these chemicals. Thus, the test is repeated in a dose-response analysis (0.0625-1 mM test chemical) and the reaction is stopped after 150 min (i.e., 10 times shorter incubation) by derivatization of the free thiol group in the peptide with monobromobimane for fluorescence-based determination of cysteine depletion (Natsch and Gfeller, 2008) . In addition, for chemicals which yielded >50% depletion at 0.0625 mM at 150 min, the test was further repeated at 15 min and 45 min, as the rate constant derived from the 150 min value would still be an underestimation.
Rate constant determination. Rate constants were determined from the different reactivity time-points as described before (Roberts and Natsch, 2009 ). For the 24 h time-point, complete depletion of the test peptide was set to 98% (because <0.002 mM of peptide is below detection limit). Depletion values <1% were set to 1%. The resulting depletion was used for rate constant determination with equation 1:
The results from dose-response analysis at earlier time points were used to determine EC50 values (concentration in mM for 50% peptide depletion). These values were transformed to rate constants according to equation 2:
For extremely reactive chemicals (i.e., >80% depletion at the 15 min time point at 0.0625 mM), the EC50 15 min is set to 0.031 mM and no shorter time points were measured. The highest rate obtained is then taken as K max (i.e., the rate determined at the earliest time point). With this approach (up to 100 times shorter incubation and 10 times lower test concentration at the lower end of the dose response), the dynamic range of the reactivity measurement is enhanced from around 2 to 5 orders of magnitude as compared with using only the 24 h depletion value. As the assay used here is not the validated DPRA protocol, it is of relevance how the two approaches correlate. We thus compared results on rate constants obtained in this study with rate constants obtained before (Natsch et al., 2011b) with full kinetic profiling under DPRA conditions (0.5 mM cysteine peptide, 5 mM maximal test concentration). Supplementary Figure S1 shows that there is a direct linear relationship between the two datasets, with the Cor1-C420 peptide being around 2.5-fold more reactive as compared with the DPRAcysteine peptide as shown before (Natsch et al., 2007) .
Physicochemical parameters: cLogP was calculated with the ChemBioDraw Ultra 12.0 software (Cambridgesoft) using the CHEMPROPPRO_LOGP function. Vapor pressure was calculated with the TIMES SS software (Laboratory of Mathematical Chemistry). Vapor pressure is considered important as chemicals are tested in the LLNA with open application, whereas evaporation is limited in the in vitro assays. Relationship of calculated vapor pressure to evaporation from the LLNA vehicle acetone/olive oil 4:1 (AOO) at 32 C was tested experimentally for 37 molecules of this study with the method described before (Delaine et al., 2011) . A linear relationship between Log (VP calc ) and Log half-life of the chemical in AOO was demonstrated as shown in Supplementary Figure S2 .
Prediction of reactivity domains based on TIMES SS and experimental adduct formation. The TIMES SS software (Version 2.27.12) was obtained from OASIS Laboratory of Mathematical Chemistry, Bourgas, Bulgaria and run using the skin sensitization metabolism-activated toxicity model. The attribution to domains was made primarily by the prediction of the alert provided by TIMES. Several alerts were merged, in cases where experimental adduct formation with the test peptide was consistent with similar reaction mechanism (thus, e.g., 1 group for S N 2/S N Ar chemicals contains chemicals with experimentally verified adduct elimination reactions at the test peptide; 1 group of Michael acceptors contains chemicals with a reactive activated double bond). In addition, in a few cases experimental adduct formation overruled the in silico prediction, justification for class attribution is then given (Supplementary Tables S11-S15). With this approach of NATSCH ET AL. | 321 combining in silico predictions with experimentally observed adducts, we aimed at a transparent and experimentally founded approach, minimizing expert judging as far as possible.
Data Transformation and Normalization for Statistical Analysis LLNA data. In case multiple LLNA data were available in our database, we took the geometric mean of the EC3 value. For statistical analysis, the pEC3 was taken as is common in modeling studies. This is a logarithmic expression taking molecular weight into account, which makes sense as also all in vitro data are expressed in mM/mM and not in weight/% as in the LLNA.
For LLNA negatives (no 3-fold induction at the highest tested concentration), the pEC3 is set to zero, which is the special case for, for example, molecules with MW of 100 and an EC3 of 100%. This approach treats all negatives equal, as not all negatives were tested up to 100%. Based on this normalization, the pEC3 of the 244 molecules spans a range from 0 for non-sensitizers to 4.86 for the most potent sensitizer oxazolone.
KeratinoSens
TM data. Chemicals are tested up to a maximal concentration of 2000 mM. Thus, for chemicals with no cytotoxicity at this concentration, the numerical IC50 is set to the arbitrary value of 4000 mM (the next higher 2-fold dilution step). Similarly, for the gene induction, if the luciferase gene is not induced above a given threshold, the value is set to 4000 mM. In addition, in the KeratinoSens TM prediction model only gene induction observed at non-cytotoxic levels (>70% viability) is considered relevant. Thus, if 1.5-fold gene induction is only observed at cytotoxic levels, then EC1.5 KS , EC2 KS and EC3 KS are set to 4000 mM. All four parameters were linearized by log transformation and normalized by: (1) multiplication by À1 to obtain increasing values for increasing potency as is the case for pEC3 and rate constant, and (ii) by addition of the constant Log(4000). That is, the logarithm of the arbitrary value of 4000 mM for inactive compounds. Equation 4 shows the example for IC50. Peptide reactivity data. These values were also normalized and linearized according to the following formula:
Where K max is the rate constant measured at the earliest time point. This normalized value is 0 for non-reactive chemicals (1% depletion at 1 mM after 24 h) and spans a linear range up to 5.33 (>80% depletion at 0.0625 mM and 15 min incubation). With these linear transformations, all in vitro parameters are set to 0 in case of a completely non-reactive, non-toxic, and non-luciferase inducing molecule, whereas all positive in vitro evidence has a positive prefix. These linear transformations do not distort the data but make reading the regression equations easier.
Vapor pressure and effect of evaporation from LLNA vehicle. Chemicals with a Log (VP calc ) < 10 Pa were found not to significantly evaporate from AOO within 60 min. Therefore, vapor pressure data were normalized as follows:
and values <zero are set to 0. With this approach chemicals predicted to evaporate significantly from mouse ears within 60 min have a positive coefficient, whereas the coefficient for chemicals with low volatility (i.e., not significantly evaporating within 60 min) is set to 0 (for experimental results and detailed rationale see Supplementary file S1.).
Statistical analysis. All statistical analysis was performed with the MiniTab 15 software. Best subset analysis was used to select the statistically most significant subsets of parameters. These were then used for multiple linear regression against the in vivo data (pEC3 or logarithmic human potency data).
Based on global regression global models were defined to predict LLNA and human data of all chemicals. The adjusted R 2 -values (in percent) and P value of the correlations are given throughout the manuscript as measures of correlation strengths. The regression equations were then used to predict the actual pEC3, EC3, and DSA 05 values of the individual chemicals. The ratio between measured and predicted EC3 value was calculated in each case in order to give the fold-misprediction. In order to avoid statistical overfit for the smaller groups of chemicals in individual domains, a leave-one-out approach was applied for the predictions within domains: Thus best subset and regression analysis was performed for each chemical on all the data within the domain but excluding the data for the chemical to be predicted. The resulting regression equation was then used to predict that particular chemical.
RESULTS
Hazard Prediction by the Two Methods
In Table 1 we present the overall predictivity of the KeratinoSens TM assay on the published set of 244 chemicals.
Different possibilities exist to predict hazard based on the LC-MS-based peptide reactivity assay. A conservative approach is to use only evidence for adduct formation for positive classification. This yields high specificity, as it avoids false-positives due to peptide oxidation, but at the cost of limited sensitivity (some sensitizers do oxidize the peptide but do not form Tables S3-S15. adducts, these are correctly predicted if peptide depletion is used for a positive rating). However, positive evidence can then be combined, rating each chemical positive which is either positive in KeratinoSens TM and/or forms direct peptide-adducts, as shown before (Emter et al., 2010) . This simple combination is presented on the set of 244 published chemicals in Table 1 , and is further used for grouping of chemicals into correct/false positives/negatives below. Including the 68 chemicals (Supplementary Table S10 ) with less clear evidence for sensitizer status, sensitivity of the combination is at 82%, specificity at 74%, and accuracy at 79% based on LLNA (n ¼ 312). If the 9 chemicals with contradictatory human and LLNA data are excluded, sensitivity is at 86%, specificity at 75%, and accuracy at 82% (n ¼ 303).
Correlation of the Individual Quantitative Parameters and Tests to LLNA Potency Next we performed correlation analysis for the 244 chemicals for the individual tests and parameters against pEC3. As shown in Table 2 , rate constant K max has the strongest individual correlation (52%), followed by EC2 KS , rate constant based on 24 h depletion only, EC1.5 KS, EC3 KS and IC50 KS . A combination of two parameters from KeratinoSens TM gives improved correlation (R 2 of around 48%, slightly below K max ). The physicochemical parameters cLogP and normalized vapor pressure on their own do not correlate to pEC3, which is expected (data not shown). In all the regression analysis we excluded surfactants, which have positive results in the LLNA with relatively low EC3 values, but are considered bona-fide false-positives (Ball et al., 2011) . Including the surfactants raises the statistical impact of cytotoxicity, but does not strongly affect the overall picture. Also two chemicals reportedly positive in the LLNA but without reported EC3 values cannot be included.
Global model to predict LLNA potency based on multiple regression analysis In order to find combinations of individual parameters, which predict LLNA potency better than single parameters, best subset analysis was applied. In this analysis, models with increasing numbers of variables are tested for increasing predictivity of the target variable. As long as adjusted R 2 is clearly increasing, the addition of further variables does increase predictivity. Table 3 lists the result on the set of 244 chemicals. Adding EC2 KS is the first parameter proposed to complement the reactivity measure. In a 3-variable model, adding vapor pressure further increases predictivity. As a fourth parameter, best subset analysis proposes to add the cytotoxicity parameter IC50 KS , still with an increase in the adjusted R 2 .
Both the models with K max , IC50 KS , VP norm and either EC1.5 KS and EC2 KS give similar predictivity of around 62% of the pEC3 in this global model. Due to very minor difference, we chose to further study below the variant including the EC1.5 KS (instead of EC2 KS ), as this value is used in the hazard prediction model and was included in the validation study.
Equation 7 gives the resulting regression equation: 
In this global model, Log K norm , Log EC1.5 norm, and Log IC50 norm do have a highly significant positive contribution to predict pEC3. The constant is small and non-significant, indicating that the regression line passes close to the origin. This makes perfect sense given that we normalized all parameters in order that they become zero in case of non-reactivity and no effects on the cells in KeratinoSens TM and given that the dataset contains a large number of non-sensitizers with a pEC3 of zero. At the same time the normalized vapor pressure gives a significant negative contribution, thus reducing the predicted potency of chemicals which evaporate significantly from mouse ears in the first hour after application. The best subset and regression analysis was separately repeated for the 144 chemicals in the dataset previously used for integrated testing strategy (ITS) and the 100 chemicals in the additional data assembled during ECVAM validation. As shown in Supplementary Data (Table S1 and S2), a similar regression equation is obtained with these two independent datasets: The statistical weight of vapor pressure, EC1.5 KS and cytotoxicity does slightly differ between the two subsets of the data, but K max has almost identical coefficients and best subset analysis gives a similar result, indicating that this global model is not highly dependent on the dataset. Equation 7 was thus used to predict the LLNA EC3 value for each chemical in the dataset of 244 chemicals, which then was compared with the in vivo value. This analysis, including (1) experimental LLNA, (2) hazard predictions by the in vitro tests, and (3) the LLNA value predicted by equation 7 for individual chemicals is shown in Supplementary Data (Supplementary Tables S3-S15 ). These data are sorted according to LLNA potency classes (Kimber et al., 2003) and the hazard predictions, and the tables also contain the domain-based predictions presented below for a comprehensive overview. A summary of this analysis is shown in Table 4 . In Figure 2 the regression of the predicted versus the measured LLNA values is plotted.
There are notable observations from this analysis. First of all it is interesting to study Supplementary Table S5-these chemicals are rated false-positive in the hazard model. It appears that they can be grouped into two classes, group A chemicals (n ¼ 18) are positive mostly due to a weak response in KeratinoSens TMinterestingly equation 7 predicts an EC3 value of ! 23% for these chemicals, in the majority of cases the predicted EC3 is higher as compared with the maximal concentration tested in the LLNA. The second group B (n ¼ 9) of chemicals is clearly positive in KeratinoSens TM and in most cases formed adducts with the test peptide-these are clearly reactive chemicals and we cannot exclude the possibility that they are false-negative in the LLNA rather than false-positive in vitro. LLNA EC3 values between 1.8 and 20 are predicted for these chemicals. Second, it is obvious that, overall, the class of extreme sensitizers is clearly under-predicted as is also obvious in Figure 2 the in vitro models and global equation 7 clearly do not have sufficient dynamic range for accurate prediction of this class; however, most extreme sensitizers are at least predicted as strong sensitizers. A similar but weaker effect is observed for the strong sensitizers, for which we have more underthan over-predictions, and the group geometric mean of the predicted LLNA EC3 is at 1.2%, whereas the measured geometric mean is at 0.32%. Table 4 lists also the number of chemicals predicted >5-fold wrong, and Table 5 lists those 12 out of 104 correct positives with weak to strong sensitization potential with >10-fold misprediction, as it is this group of chemicals which may best teach us for which chemicals this testing strategy and a global model is poor and needs significant improvement.
Next to the 244 chemicals in the ECVAM dataset and in Natsch et al. (2013) , we assembled in vitro data for the chemicals in Supplementary Table S10 (Supplementary Tables S3-S15 ). This set of chemicals contains a number of chemicals with incongruent human and animal data or LLNA data only. In addition most LLNA results come from a single study and some of the LLNA values are only from secondary citations and the original study cannot be retrieved, these limitations are indicated in Supplementary Table S10 for individual chemicals. Therefore, overall there is less solid in vivo evidence and this dataset was treated separately and not used to derive the global model. Nevertheless, equation 7 was also used to predict potency for chemicals in this independent set, and results are shown in Supplementary Table S10. Fold misprediction overall is higher for this set of chemicals, geometric mean of misprediction is 4.0-fold, excluding the chemicals with contradictory evidence, and 4.9-fold including these chemicals. Overpredicted chemicals, chemicals with a predicted LLNA value which is >5 times below the in vivo value. e Value given in italics-prediction model rates these chemicals negative (no adduct and no gene induction at non-cytotoxic levels). Equation 7 still calculates a pEC3 which must not be 0 either due to peptide depletion by oxidation and/or cytotoxicity. 
Correlation to Human Potency Data and a Global Model to Predict Human Potency Based on Multiple Regression
One of the most comprehensive datasets on human LOEL data expressed as DSA 05 has been published by ICCVAM when validating the LLNA for human potency predictions (ICCVAM, 2011). We next calculated global models of in vitro data versus human data for this dataset. The original ICCVAM file contains 63 chemicals with positive LLNA and human LOEL. The logarithmic correlation between human dose and the LLNA EC3 (in mg/cm 2 ) gives an R 2 of 45%. Out of this dataset we could test 60 chemicals in KeratinoSens TM , excluding two natural extracts (Oakmoss and YlangYlang) and one chemical which was not clearly defined ("Acetylisovaleryl"). Only 52 substances were also tested in the peptide reactivity assay, as metals and extracts are not compatible with this assay. The ICCVAM database contains additional 13 chemicals, which were reported positive in humans but not in the LLNA, 11 of these were also tested in vitro. Thus, we do have different subsets within this dataset (i.e., chemicals correct positive in LLNA and/or in vitro) and therefore correlations between in vitro data or LLNA data with the human data for different subsets are presented in Table 6 . All these correlations are significant at P < .0005. More details on the regression equations and predictions at the level of individual chemicals are shown in Supplementary Data (Table S16 ). (Figure 3b and d) .
Overall, the LLNA gives variable R 2 values to predict human potency for these subsets in the range of 37-49%. From the in vitro data the EC3 in KeratinoSens TM appears the best predictor for this dataset, and we observe a smaller contribution for reactivity. No contribution comes from volatility consistent with the fact that (unlike the LLNA) human predictive tests are conducted under occlusion thus inhibiting evaporation. Depending on the subset analyzed, the R 2 between in vitro and human data is in the range of 32-50%. If only chemicals rated positive by the in vitro assays are included, the correlation is very similar as compared with the correlation between human data and LLNA data for the LLNA-positives.
Classification of the Dataset into Mechanistic Domains
All 312 chemicals were processed through the TIMES SS software. TIMES itself is set up to predict three potency classes (non-sensitizers, weak, and moderate-extreme)-here we did not use this class-prediction result but only the prediction of a NATSCH ET AL. | 325 structural alert. In case no direct acting alert was predicted-the alert for most potent putative metabolite was taken. These results were aligned with the reactivity data from the LC-MS analysis and used to group chemicals into mechanistic domains. Five domains contain >10 chemicals (in total n ¼ 142) and were further studied for prediction within domains. The structures, TIMES prediction, LC-MS result, class assignment, and rationale for class assignments are given for individual chemicals in Supplementary Tables S11-S15 .
Correlation to and Prediction of LLNA Potency within Domains
Predictions within domains were made based on a leave-one-out approach. In parallel regression analysis on all chemicals within the domain was performed to analyze which parameters contribute strongest in which domain. The latter analysis is shown in detail in Supplementary Data ( Figure S3-S7 ), the summary of the regression analysis and results of the leave-one-out approach is presented in Table 7 and Figure 4 . Results for individual chemicals are given in Supplementary Tables S11-S15. The fold misprediction is, with the exception of the aldehyde domain, in each case reduced when moving from the global analysis to the domain models with the leave-one-out approach. Best predictions are achieved for Michael acceptors, epoxides, and chemicals reacting by addition-elimination. Fold misprediction in these classes has a geometric mean of 2-to 2.6-fold. This detailed analysis indicates that both the global and the domain models are less accurate for pre/prohaptens predicted by TIMES SS as precursors of "Quinone methide(s)/ imines, Quinoide oxime structure, Nitroquinones" (further referred to as "pre-quinone-domain"). Also, prediction of aldehydes is not satisfactory as discussed below.
The other key learning from Table 7 is that different parameters are best predictors within different mechanistic domains. Thus, rate constant is the most prominent predictor for chemicals in the S N 2/S N Ar domain while EC3 KS best predicts Michael acceptors and cytotoxicity and vapor pressure have strongest contribution to predict the epoxides in this dataset. This does not indicate that the other parameters have no correlation within the respective domains, given are just the parameters with the best predictive power.
Combination of the Global and the Domain Models
Not all chemicals fall into one of the well-defined domainsthus, a practical way forward is to combine the predictions with the domain models if available and use predictions of the global model if not, as proposed in Figure 1 . In Figure 5 , the scatter plot for this analysis is shown. As is evident from this graph, few of the chemicals predicted with the domain-based models (open triangels) are mispredicted >5-fold.
Case Studies: Example of Predictions for Some Key Human Contact Allergens
The presented analysis shows global correlations, and data on all individual chemicals can be retrieved from Supplementary Data. Nevertheless, it is illustrative to show some examples, and we chose to present in Table 8 chemicals for which frequent positive human patch tests were reported and which are therefore considered relevant human allergens. This Table  aligns predictions of human data by LLNA and by in vitro results, and compares global-and domain-based LLNA predictions.
GHS Potency Classification Based on the LLNA and Human Predictions
Besides using potency data for risk assessment, for which we ideally predict a discrete point of departure and not a potency NATSCH ET AL. | 327 class, potency prediction also becomes of regulatory relevance for subclassification of sensitizers into class 1A and 1B in the Globally Harmonized System of Classification and Labelling of Chemicals (GHS), that is, to split chemicals into weak and strong sensitizers based on LLNA EC3 threshold of 2% or a human DSA 05 of 500 mg/cm 2 . In order to evaluate how good this discrimination is possible with the regression analysis presented here we grouped chemicals based on GHS thresholds. Table 9 lists the results for the human dataset classified according the GHS threshold DSA 05 of 500 mg/cm 2 (n ¼ 71, chemicals tested at least in KeratinoSens TM ) and classified by both LLNA and in vitro data. As compared with the LLNA predictions (Supplementary equation S5) , there are more false-negatives based on the in vitro data, on the other hand Supplementary equation S4 predicting human potency with in vitro data gives a quite good discrimination between GHS classes 1A and 1B, and prediction of human class 1A is even better as compared with prediction by LLNA. Table 10 shows LLNA-based GHS classes predicted by in vitro data both either using the global model only or using the refined data from the domain models where available. For the set of 244 chemicals, the accuracy for classification into the 3 classes (NS; 1B, and 1A) is at 71% using the global model and at 75% using the combination of domain and global models. Adding the 59 of the 68 molecules in Supplementary Table S10, for which there is no strongly contradictory sensitization evidence, the 3-class accuracy is at 67% using the global model and at 71% using the combination of domain and global models.
A Global Model Integrating h-CLAT Data
The third endpoint, for which recently OECD draft guideline and ECVAM recommendations were published, is dendritic cell activation measured in the h-CLAT assay. Compared with the database presented here, data on fewer chemicals are available for h-CLAT, and thus the comparison of global and local models including this additional endpoint cannot yet be made due to lower number of chemicals in the different domains. Still, we evaluated the contribution of h-CLAT data when constructing a global regression model. For 128 chemicals we could retrieve h-CLAT data from the literature. H-CLAT reports four parameters: CV75 for the dose causing 25% cytotoxicity, EC150 for the dose stimulating CD86 expression and EC200 for the dose stimulating CD54. MIT is the lower of the 2 latter variables, and was described as a key parameter for potency assessment (Nukada et al., 2011 (Nukada et al., , 2012 . All 4 parameters were Log-transformed and normalized to zero for inactive compounds as done for the KeratinoSens TM data. Table 11 gives results from correlation analysis. A slightly different regression result is obtained for this subset of chemicals when using physicochemistry data, reactivity and KeratinoSens TM (Model 1), with EC3 KS being preferred over EC1.5 KS for this subset. Adding h-CLAT (Model 2) improves R 2 by only 4%, and the mean fold-misprediction is only reduced from 3.23 to 3.05. More importantly the correlation between pEC3 predicted by Models 1 and 2 has an R 2 of 92.3%
(data not shown), indicating that both models predict very similar EC3 values also at the level of individual chemicals. Using h-CLAT instead of Keratinosens TM together with reactivity (Model 3) gives slightly improved but very similar prediction (Fold misprediction is 3.12 instead of 3.23). Interestingly, correlation between pEC3 predicted by Models 1 and 3 has an R 2 of 88%,
indicating that the two cell-based endpoints do contain significantly redundant information. 
DISCUSSION
The main conclusion from this study is that quantitative readouts from the in vitro Nrf2-assay and the in chemico peptide reactivity assay do significantly contribute to the prediction of sensitizer potency in both mice and man. Overall, a more accurate prediction is possible by models within mechanistic domains, yet not all sensitizers belong to sufficiently populated domains and therefore combining both approaches is a practical way forward. The endpoints used here were proposed as part of an integrated testing approach for hazard determination (ECVAM, 2014a,b) , and the current data evaluation indicates what they can and cannot contribute to potency assessment. The variability of the in vivo data should be taken into account, originating from two sources: test variability and variability between laboratories (the reference databases come from multiple centres and were built up over two decades for the LLNA and 3-4 decades for the human data). Repeated LLNA values in the ICCVAM database vary 1.7-to 2-fold on either side of the mean (ICCVAM, 2008) and therefore a 2-fold misprediction of an EC3 may still fall within the variability of the true in vivo outcome. The uncertainty is even higher for the human data obtained with different test protocols. Correlation of the LLNA with the human LOEL is far from perfect (ICCVAM, 2011), which can partly be attributed to these limitations in the human dataset.
There are a number of more specific findings which warrant discussion: (1) Differences in prediction accuracy across potency classes, (2) different parameters contributing to prediction in mechanistic domains, (3) different parameters describing human and LLNA potency, (4) global versus domain models, (5) other statistical/mathematical approaches for data integration, and (6) data redundancy.
Prediction Accuracy by Global Regression Differs Between Potency Classes
The regression line of the global model has a slope <1, mainly due to under-predictions in the strong and extreme classes. Still, in 39 of 43 cases, the strong/extreme sensitizers are predicted with an LLNA <5%, and in 27 of 43 cases <1%-hence a significant sensitization potential would be predicted for most of these chemicals. More specific testing may then be needed for these chemicals: for some strong/extreme sensitizers, a specific stable modification of amine groups was reported (Fleischel et al., 2009; Natsch et al., 2010 Natsch et al., , 2012 , and more closely evaluating the reaction rate and adduct stability with amine groups might correct some under-predictions, and we have shown this in detail in the case of oxazolone Interestingly, for many strong and extreme sensitizers the domain-based assessment yielded lower and more accurate EC3 predictions. The average fold-misprediction by the global model is lower for moderate and weak sensitizers, indicating higher accuracy in this range. Interestingly, false-positives are mostly predicted extremely weak and in a number of cases, above the maximal test dose in the LLNA, thus the potency assessment partly corrects for the hazard misclassifications.
Different Parameters Contribute to Potency Prediction in Different Mechanistic Domains
Not all mechanistic domains are best predicted by the same in vitro endpoint. Reactivity rate constants contribute most to predictions in the S N 2/S N Ar domain, and KeratinoSens TM predicts the Michael acceptor domain particularly well. This observation indicates that further work to improve potency assessment must not necessarily focus on finding 'a new ideal assay' to better predict potency of all chemicals, but to develop more specific testing schemes for domains in which prediction currently is insufficient. To name an example, peptide reactivity data correlate poorly with potency of aldehydes-this can be explained by the fact that Schiff Base formation is not usually observed under conditions of the peptide reactivity tests (Natsch et al., 2011b) , and a more specific test for Schiff Base formation may be applied to these chemicals. The epoxides present another interesting case: they are best predicted by cytotoxicity and volatility, in agreement with an earlier study on a subset of the current set (Delaine et al., 2011) . Does this indicate that reactivity does not contribute to the sensitization potential? Most tested epoxides contain an identical glycidyl group critical for the sensitization potential (O'Boyle et al., 2012) , and due to this identical reactive group the differences in reactivity are relatively small (Niklasson et al., 2009) . Reactivity is clearly a prerequisite for their sensitization potential, but the potency differences in the LLNA may be critically governed by differential loss due to volatility and differences in triggering of , this domain-specific effect may influence the correlation with human data. Still it is interesting that for chemicals positive both in the LLNA and the in vitro hazard assessment, the correlation of LLNA EC3 and in vitro data to human potency are in a similar range.
Different Improvements when Moving from Global to Domain-Based Assessment For the 79 chemicals attributed to the S N 2/S N Ar-, Michael acceptor and epoxide domains, the leave-one-out predictions are clearly improved versus the global model (misprediction was reduced from 3.2-to 2.3-fold), not too far away from the variability of the LLNA. These domains are nicely defined according Figure 1 : peptide adducts are mostly observable and consistent with the TIMES prediction. A different case is the aldehyde-domain: here improved prediction by the domainbased model is not convincing and may best be corrected by a more specific reactivity test. A more difficult case is the "pre-quinone-domain". The misprediction by the global model is higher-probably due to limited metabolic and oxidative capacity of the test systems. But also the improvement with the domain-based assessment is limited. For a number of chemicals, adduct formation consistent with abiotic oxidation to a quinone and subsequent addition to the peptide were observed, but it is unclear whether all the remaining chemicals attributed to this domain would be enzymatically activated in the skin and sensitize by the proposed mechanism. Thus, attribution to this domain is more uncertain due to limited understanding of in vivo prohapten metabolism and it is the domain in which quantitative predictions are most difficult.
With the domain-based regression models, we may not fully use the potential of in vitro data for read-across. Some chemicals are attributed to domains with few chemicals, making regression analysis prone to errors (and thus not explored here). Phthalic anhydride, 1,2-cyclohexandicarboxylic acid anhydride, and maleic anhydride led to complete peptide depletion and adduct formation at both Lys-residues of the peptide. By the global model, these chemicals are strongly underpredicted due to inactivity in the KeratinoSens TM assay and lack of a kinetic binding parameter for the Lys-residue. However, a risk assessor confronted with peptide reactivity data on a new anhydride may use the existing data to support read-across even in absence of a specific regression model.
Deterministic Versus Probabilistic Models
Here we used regression as a classical way of building a model based on multiple continuous parameters. This has the advantage of (1) being transparent, (2) indicating importance of parameters in different domains and in mice versus Human, and (3) avoiding data-loss when performing classifications, yet it must not be the optimal approach. Strong support for using probabilistic approaches in integrated testing strategies had been presented (Jaworska and Hoffmann, 2010) , and Bayesian statistics were applied to predict sensitization potency classes (Jaworska et al., 2011 . Ways to use these tools to predict a discrete point of departure for QRA will now be needed.
As compared with regression analysis, a probabilistic approach may contribute more weight to a specific strong outcome from one particular test-even if another test is negative, this second outcome must not 'dilute' the other indication. Such conflicts in data can be handled by probabilistic models, whereas regression analysis provides a weight-of-evidence approach.
Data Redundancy
Comparison of the models with KeratinoSens TM , reactivity and h-CLAT versus the models with reactivity and KeratinoSens TM or h-CLAT indicated that the three models give highly similar predictions. This indicates that different assays, even addressing different steps in the adverse outcome pathway (AOP), may yield partly redundant information. Thus, this analysis may somewhat dampen the general hope, that by integrating information from multiple endpoints along the AOP, the predictivity will continue to increase. However, this does not exclude the possibility that probabilistic statistics and domain-based models will better harness additional information obtained by the added endpoints.
Use of the Models
The current analysis is a step towards potency assessment and shows the limitations. For a new chemical falling in one of the well-predicted domains, the domain-based prediction of a "probable EC3" may be sufficient to allow determination of a point of departure for a confirmatory HRIPT (performed below the expected NESIL), at least when setting the dose of this confirmatory test at least 2-fold below the dose one would use based on the measured EC3. For chemicals in poorly populated domains, one might need further data and verify that the additional evidence would lead to a similar point of departure as obtained with the global regression model.
The Way Forward
Specific further work may still focus on assay improvements specifically addressing quantitative predictions, to just mention a few: (1) currently peptide depletion assays do not distinguish between rate of peptide oxidation and rate of peptide adduction, (2) no fully standardized assay for Schiff Base formation was explored in detail, (3) improvements are still needed to quantitatively predict prohaptens, (4) no kinetic assay is available for kinetic binding to lysine residues, (5) quantitatively addressing pathways of danger signal formation (Martin, 2012) may further increase potency predictions, and (6) epidermal model-based tests were proposed for potency predictions (Gibbs et al., 2013 ) but need to be tested on much larger numbers of chemicals to evaluate their accuracy to predict a point of departure.
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